CLAIMS

1) Use of angelica extract in the manufacture of a medicament for inhibiting the expression of atherogenic microRNA-24, microRNA-125, and for inducing the expression of antiatherogenic microRNA 126, microRNA-222, microRNA-let7b in human blood plasma, in which the preparation is obtained by drying the roots of the angelica plant for one week at 24±1°C, the dried roots are then ground into a powder, after which 100 g of ground angelica is added to 100 ml of distilled water, mixed, after which the obtained mixture is boiled in a water bath for 1 to 3 hours, until the volume of the liquid has been reduced by 10-fold, centrifuged at 15000 RPM for 30 minutes at 24±1°C, after which the obtained supernatant is filtered on a Whatman filter 1, and the solution is further concentrated with a Concentrator plus rotary evaporator (Eppendorf) and a WP6122050 pump (Millipore) under the following conditions: 1400 RPM, temperature 30°C, for 16 hours with a 10 mbar vacuum, after which 5 ml of the obtained aqueous extract are dissolved in a 0.9% aqueous sodium chloride solution at a ratio of 1:5, after which the obtained preparation is administered to the patient *per os* in a quantity of 5 drops per 10 kg of their body weight once a day for 4 weeks.